

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4660331

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SANG GEUN PARK	10/11/2017
HYE GYEONG SHIN	10/11/2017
JEONG WOO BAE	10/11/2017
HYUN JU CHOI	10/11/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NAVIPHARM CO., LTD.
<b>Street Address:</b>	5, JANGAN-RO 448BEON-GIL, JANGAN-GU, SUWON-SI,
<b>City:</b>	GYEONGGI-DO
<b>State/Country:</b>	KOREA, REPUBLIC OF
<b>Postal Code:</b>	16209
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	KR2016004380
<b>Application Number:</b>	15569693
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)783-6031
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	202-783-6040
<b>Email:</b>	knogami@rfem.com, pto-pat-email@rfem.com
<b>Correspondent Name:</b>	ROTHWELL, FIGG, ERNST & MANBECK, P.C.
<b>Address Line 1:</b>	607 14TH STREET, N.W.
<b>Address Line 2:</b>	SUITE 800
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	3738-137
<b>NAME OF SUBMITTER:</b>	AYDIN H. HARSTON, PH.D., 65,249
<b>SIGNATURE:</b>	/Aydin H. Harston/
<b>DATE SIGNED:</b>	10/26/2017
<b>Total Attachments: 2</b>	

source=Assignment#page1.tif

source=Assignment#page2.tif

**ASSIGNMENT BY INVENTOR(S) OF PATENT APPLICATION FOR ALL COUNTRIES**

BE IT KNOWN THAT, for good and valuable consideration paid to the undersigned inventor(s) (hereinafter ASSIGNOR(S)) by

Name: NAVIPHARM CO., LTD.  
Address: 5, Jangan-ro 448beon-gil, Jangan-gu, Suwon-si,  
Gyeonggi-do 16209, Republic of Korea

(hereinafter ASSIGNEE),

the receipt and adequacy of which is hereby acknowledged, ASSIGNOR(s) hereby sell(s), assign(s) and transfer(s) to ASSIGNEE

all of his/her right, title and interest in, to and under the invention and application entitled:

**RIVASTIGMINE-CONTAINING SUSTAINED-RELEASE  
PHARMACEUTICAL COMPOSITION**

for which application for Letters Patent of the United States ASSIGNOR(S) is/are the sole or a joint inventor and which application was executed on even date herewith or is identified as follows

U.S. Serial No. or PCT Appln. No.: PCT/KR2016/004380 Filing Date: April 27, 2016

*(Rothwell, Figg, Ernst & Manbeck is hereby authorized to insert the series code, serial or application number and/or filing date hereon, when known)*

and all Letters Patent of the United States to be obtained on said application or on any continuation, division, reissue, reexamination or extension thereof and all rights connected therewith, and all applications for Letters Patent which may hereafter be filed for said invention in any country or countries foreign to the United States, and all Letters Patent which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all rights of priority in any such country or countries based upon the filing of the said application for Letters Patent of the United States which are created by any law, treaty or international convention, for the full term or terms for which the same may be granted, including all rights to recover damages for any and all past infringement; and





ASSIGNOR(S) agree(s) to execute all papers necessary in connection with said application and any continuing, divisional, reissue or reexamination applications thereof and to execute separate assignments in connection with such applications as ASSIGNEE may deem necessary.

ASSIGNOR(S) agree(s) to execute all papers necessary in connection with any interference, litigation, or other legal proceeding which may be declared concerning this application or any continuation, division, reissue or reexamination thereof or Letters Patent, reissue patent or reexamination certificate issued thereon and to cooperate with ASSIGNEE in every way possible in obtaining and producing evidence and proceeding with such interference, litigation, or other legal proceeding.


ASSIGNOR(S) covenant(s) that he/she has the full right to convey the entire interest herein assigned and has not executed, and will not execute, any agreement in conflict herewith.

ASSIGNOR(S) acknowledge(s) that ASSIGNEE may appoint any attorney or practitioner of ASSIGNEE'S choice to prosecute any application or other legal proceeding involving said invention and ASSIGNOR(S) further acknowledge(s) that any attorney or practitioner so appointed by ASSIGNEE does not represent ASSIGNOR(S) and that such appointment by ASSIGNEE does not create any attorney-client relationship between ASSIGNOR(S) and any attorney or practitioner appointed by ASSIGNEE.

IN WITNESS WHEREOF, ASSIGNOR(S) has/ have affixed his/her signature below.

Signature: 	Date: 2017. 10. 11
Typed Name: <b>PARK, Sang Geun</b>	
Signature: 	Date: 2017. 10. 11
Typed Name: <b>SHIN, Hye Gyeong</b>	
Signature: 	Date: 2017. 10. 11
Typed Name: <b>BAE, Jeong Woo</b>	
Signature: 	Date: 2017. 10. 11
Typed Name: <b>CHOI, Hyun Ju</b>	

WITNESSES: (optional)	
Signature:	Date:
Typed Name:	
Signature:	Date:
Typed Name:	

<b>ACCEPTED AND ACKNOWLEDGED FOR AND ON BEHALF OF THE ASSIGNEE:</b>	
Assignee Name:	<b>NAVIPHARM CO., LTD.</b>
Signature of Authorized Person:	
Typed/Printed Name of Authorized Person:	Lee Chang-kyoo
Title:	The Representative of Navipharm Co., Ltd.
Date:	11, October, 2017

**NO LEGALIZATION REQUIRED. THIS DOCUMENT MAY BE NOTARIZED IF DESIRED FOR FURTHER PROOF OF EXECUTION.**